Cargando…

Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities

Metabolic and neurodegenerative disorders have a growing prevalence in Western countries. Available epidemiologic and neurobiological evidences support the existence of a pathophysiological link between these conditions. Glucagon-like peptide 1 (GLP-1), whose activity is reduced in insulin resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Mossello, Enrico, Ballini, Elena, Boncinelli, Marta, Monami, Matteo, Lonetto, Giuseppe, Mello, Anna Maria, Tarantini, Francesca, Baldasseroni, Samuele, Mannucci, Edoardo, Marchionni, Niccolò
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124026/
https://www.ncbi.nlm.nih.gov/pubmed/21747826
http://dx.doi.org/10.1155/2011/281674
_version_ 1782207035866087424
author Mossello, Enrico
Ballini, Elena
Boncinelli, Marta
Monami, Matteo
Lonetto, Giuseppe
Mello, Anna Maria
Tarantini, Francesca
Baldasseroni, Samuele
Mannucci, Edoardo
Marchionni, Niccolò
author_facet Mossello, Enrico
Ballini, Elena
Boncinelli, Marta
Monami, Matteo
Lonetto, Giuseppe
Mello, Anna Maria
Tarantini, Francesca
Baldasseroni, Samuele
Mannucci, Edoardo
Marchionni, Niccolò
author_sort Mossello, Enrico
collection PubMed
description Metabolic and neurodegenerative disorders have a growing prevalence in Western countries. Available epidemiologic and neurobiological evidences support the existence of a pathophysiological link between these conditions. Glucagon-like peptide 1 (GLP-1), whose activity is reduced in insulin resistance, has been implicated in central nervous system function, including cognition, synaptic plasticity, and neurogenesis. We review the experimental researches suggesting that GLP-1 dysfunction might be a mediating factor between Type 2 diabetes mellitus (T2DM) and neurodegeneration. Drug treatments enhancing GLP-1 activity hold out hope for treatment and prevention of Alzheimer's disease (AD) and cognitive decline.
format Online
Article
Text
id pubmed-3124026
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-31240262011-07-11 Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities Mossello, Enrico Ballini, Elena Boncinelli, Marta Monami, Matteo Lonetto, Giuseppe Mello, Anna Maria Tarantini, Francesca Baldasseroni, Samuele Mannucci, Edoardo Marchionni, Niccolò Exp Diabetes Res Review Article Metabolic and neurodegenerative disorders have a growing prevalence in Western countries. Available epidemiologic and neurobiological evidences support the existence of a pathophysiological link between these conditions. Glucagon-like peptide 1 (GLP-1), whose activity is reduced in insulin resistance, has been implicated in central nervous system function, including cognition, synaptic plasticity, and neurogenesis. We review the experimental researches suggesting that GLP-1 dysfunction might be a mediating factor between Type 2 diabetes mellitus (T2DM) and neurodegeneration. Drug treatments enhancing GLP-1 activity hold out hope for treatment and prevention of Alzheimer's disease (AD) and cognitive decline. Hindawi Publishing Corporation 2011 2011-06-01 /pmc/articles/PMC3124026/ /pubmed/21747826 http://dx.doi.org/10.1155/2011/281674 Text en Copyright © 2011 Enrico Mossello et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Mossello, Enrico
Ballini, Elena
Boncinelli, Marta
Monami, Matteo
Lonetto, Giuseppe
Mello, Anna Maria
Tarantini, Francesca
Baldasseroni, Samuele
Mannucci, Edoardo
Marchionni, Niccolò
Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities
title Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities
title_full Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities
title_fullStr Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities
title_full_unstemmed Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities
title_short Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities
title_sort glucagon-like peptide-1, diabetes, and cognitive decline: possible pathophysiological links and therapeutic opportunities
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124026/
https://www.ncbi.nlm.nih.gov/pubmed/21747826
http://dx.doi.org/10.1155/2011/281674
work_keys_str_mv AT mosselloenrico glucagonlikepeptide1diabetesandcognitivedeclinepossiblepathophysiologicallinksandtherapeuticopportunities
AT ballinielena glucagonlikepeptide1diabetesandcognitivedeclinepossiblepathophysiologicallinksandtherapeuticopportunities
AT boncinellimarta glucagonlikepeptide1diabetesandcognitivedeclinepossiblepathophysiologicallinksandtherapeuticopportunities
AT monamimatteo glucagonlikepeptide1diabetesandcognitivedeclinepossiblepathophysiologicallinksandtherapeuticopportunities
AT lonettogiuseppe glucagonlikepeptide1diabetesandcognitivedeclinepossiblepathophysiologicallinksandtherapeuticopportunities
AT melloannamaria glucagonlikepeptide1diabetesandcognitivedeclinepossiblepathophysiologicallinksandtherapeuticopportunities
AT tarantinifrancesca glucagonlikepeptide1diabetesandcognitivedeclinepossiblepathophysiologicallinksandtherapeuticopportunities
AT baldasseronisamuele glucagonlikepeptide1diabetesandcognitivedeclinepossiblepathophysiologicallinksandtherapeuticopportunities
AT mannucciedoardo glucagonlikepeptide1diabetesandcognitivedeclinepossiblepathophysiologicallinksandtherapeuticopportunities
AT marchionniniccolo glucagonlikepeptide1diabetesandcognitivedeclinepossiblepathophysiologicallinksandtherapeuticopportunities